Ooo_老虎社区_美港股上老虎

Freddyd
2021-07-22

Ooo

Warburg Pincus-Backed AI Drug Firm Insilico Weighs U.S. IPO

(Bloomberg) -- Insilico Medicine, a company that uses artificial intelligence to drive drug discover

Warburg Pincus-Backed AI Drug Firm Insilico Weighs U.S. IPO

免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。

推荐
最新

暂无评论

热议股票

关于我们·老虎社区守则·老虎社区账号管理规范·老虎社区服务协议·老虎社区隐私政策

公司名称：北京至简风宜信息技术有限公司

违法和不良信息投诉：010-5681-3562（工作时间9:30-18:30）

邮箱：service@laohu8.com

营业执照：91110105MA01A4U55R

ICP备：京ICP备18016422号

网安备：京公网安备11010502036490

关注我们

{"i18n":{"language":"zh_CN"},"data":{"magic":2,"id":172380975,"tweetId":"172380975","gmtCreate":1626935856697,"gmtModify":1633769573532,"author":{"id":3574854386909318,"idStr":"3574854386909318","authorId":3574854386909318,"authorIdStr":"3574854386909318","name":"Freddyd","avatar":"https://static.tigerbbs.com/7967e4125926fdf32d9965f6fe32519d","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":7,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":22,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><p>Ooo</p></body></html>","htmlText":"<html><head></head><body><p>Ooo</p></body></html>","text":"Ooo","highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/172380975","repostId":1157055369,"repostType":4,"repost":{"id":"1157055369","kind":"news","pubTimestamp":1626932797,"share":"https://www.laohu8.com/m/news/1157055369?lang=&edition=full","pubTime":"2021-07-22 13:46","market":"us","language":"en","title":"Warburg Pincus-Backed AI Drug Firm Insilico Weighs U.S. IPO","url":"https://stock-news.laohu8.com/highlight/detail?id=1157055369","media":"Bloomberg","summary":"(Bloomberg) -- Insilico Medicine, a company that uses artificial intelligence to drive drug discover","content":"<p>(Bloomberg) -- Insilico Medicine, a company that uses artificial intelligence to drive drug discovery, is considering a U.S. initial public offering that could raise about $300 million, according to people familiar with the matter.</p>\n<p>The Hong Kong-based firm is in talks with investment banks about a possible first-time share sale as soon as later this year, the people said, asking not to be identified because the matter is private.</p>\n<p>No final decisions have been made and details such as size, timing and venue could change, the people said. Insilico could also opt to do another private funding round, they said.</p>\n<p>Insilico founder and Chief Executive Officer Alex Zhavoronkov declined to comment.</p>\n<p>Founded in 2014, Insilico works with pharmaceutical and biotechnology companies and uses AI to help improve their research and development capabilities, according to its website. The firm’s technology has helped generate drug candidates and complete pre-clinical studies to treat a pulmonary disease. Its partners include U.S. pharma giants Pfizer Inc. and Johnson &amp; Johnson, and Japanese drugmakers Astellas Pharma Inc. and Taisho Pharmaceutical Holdings Co.</p>\n<p>The company has also partnered with Syngenta Group, the Swiss seed and fertilizer business owned by China National Chemical Corp., on the discovery of novel molecules for sustainable regenerative farming.</p>\n<p>Insilico raised $255 million in June in a series C financing led by private equity firm Warburg Pincus. Existing investors including Qiming Venture Partners and Baidu Ventures, the venture capital arm of Chinese search giant Baidu Inc., also participated in the round. OrbiMed, Mirae Asset Capital and Sequoia Capital China are among the new backers.</p>","source":"lsy1612507957220","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Warburg Pincus-Backed AI Drug Firm Insilico Weighs U.S. IPO</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWarburg Pincus-Backed AI Drug Firm Insilico Weighs U.S. IPO\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-22 13:46 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/warburg-pincus-backed-ai-drug-035541170.html><strong>Bloomberg</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>(Bloomberg) -- Insilico Medicine, a company that uses artificial intelligence to drive drug discovery, is considering a U.S. initial public offering that could raise about $300 million, according to ...</p>\n\n<a href=\"https://finance.yahoo.com/news/warburg-pincus-backed-ai-drug-035541170.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"WPCA":"Warburg Pincus Capital I-A Corp"},"source_url":"https://finance.yahoo.com/news/warburg-pincus-backed-ai-drug-035541170.html","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1157055369","content_text":"(Bloomberg) -- Insilico Medicine, a company that uses artificial intelligence to drive drug discovery, is considering a U.S. initial public offering that could raise about $300 million, according to people familiar with the matter.\nThe Hong Kong-based firm is in talks with investment banks about a possible first-time share sale as soon as later this year, the people said, asking not to be identified because the matter is private.\nNo final decisions have been made and details such as size, timing and venue could change, the people said. Insilico could also opt to do another private funding round, they said.\nInsilico founder and Chief Executive Officer Alex Zhavoronkov declined to comment.\nFounded in 2014, Insilico works with pharmaceutical and biotechnology companies and uses AI to help improve their research and development capabilities, according to its website. The firm’s technology has helped generate drug candidates and complete pre-clinical studies to treat a pulmonary disease. Its partners include U.S. pharma giants Pfizer Inc. and Johnson & Johnson, and Japanese drugmakers Astellas Pharma Inc. and Taisho Pharmaceutical Holdings Co.\nThe company has also partnered with Syngenta Group, the Swiss seed and fertilizer business owned by China National Chemical Corp., on the discovery of novel molecules for sustainable regenerative farming.\nInsilico raised $255 million in June in a series C financing led by private equity firm Warburg Pincus. Existing investors including Qiming Venture Partners and Baidu Ventures, the venture capital arm of Chinese search giant Baidu Inc., also participated in the round. OrbiMed, Mirae Asset Capital and Sequoia Capital China are among the new backers.","news_type":1},"isVote":1,"tweetType":1,"viewCount":391,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"EN","currentLanguage":"EN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":3,"xxTargetLangEnum":"ORIG"},"commentList":[],"hasMoreComment":false,"orderType":2}